Integer Holdings (ITGR) Stock Forecast & Price Target

Integer Holdings is supported by a durable medtech components franchise that delivered a Q1 top- and bottom-line beat, with sales of $440M and adjusted EPS of $1.20, aided by both Cardio & Vascular and Cardiac & Neuro outperforming expectations. Although gross margin of 24.9% and adjusted operating margin of 7.2% missed targets, management’s view that full-year guidance cuts reflect one-time customer forecast updates rather than structural weakness is encouraging, especially given the core EP market is still growing in the high-teens. The strategic review following heightened inbound interest also underscores the company’s attractive valuation and long-term recovery potential as market stabilization develops.

Integer Holdings is facing a weakening fundamental profile, with 2Q26 revenue down 2.6% year over year to $464.1 million and adjusted EPS slipping to $1.60 from $1.65, while 3Q26E calls for a further revenue decline to $450.5 million and EPS of $1.63. The company’s full-year 2026 outlook was cut across the board, with midpoint revenue guidance lowered by $31 million to flat-to-2% decline, adjusted operating income reduced by $19 million, and adjusted EPS cut by $0.42, reflecting softer customer forecasts and market dynamics. Margin pressure from lower gross margins and higher overhead tied to recent investments, combined with reduced disclosure after withdrawing guidance for the pending KKR transaction, supports a cautious negative stance.